WARNING: HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS Serious and fatal hypersensitivity adverse reactions, including anaphylaxis, can occur with oxaliplatin within minutes of administration and during any cycle. Oxaliplatin is contraindicated in patients with hypersensitivity reactions to oxaliplatin and other platinum-based drugs [see Contraindications (4)].
Immediately and permanently discontinue oxaliplatin for hypersensitivity reactions and administer appropriate treatment for management of the hypersensitivity reaction [see Warnings and Precautions (5.1)]. WARNING: HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS See full prescribing information for complete boxed warning.
Serious and fatal hypersensitivity adverse reactions, including anaphylaxis, can occur with oxaliplatin within minutes of administration and during any cycle. Oxaliplatin is contraindicated in patients with hypersensitivity reactions to oxaliplatin and other platinum-based drugs. Immediately and permanently discontinue oxaliplatin for hypersensitivity reactions and administer appropriate treatment.
(4, 5.1)
Use: Labeled indications
- adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer.
- treatment of advanced colorectal cancer.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (1) treatment of advanced colorectal cancer. (1)
Contraindications
4 CONTRAINDICATIONS Oxaliplatin is contraindicated in patients with a history of a hypersensitivity reaction to oxaliplatin or other platinum-based drugs. Reactions have included anaphylaxis [see Warnings and Precautions (5.1)]. History of hypersensitivity reaction to oxaliplatin or other platinum-based drugs. (4, 5.1)
US FDA labelDosing: Adult
- Administer oxaliplatin injection 85 mg/m 2 as an intravenous infusion over 120 minutes concurrently with leucovorin over 120 minutes in separate bags, followed by fluorouracil on Day 1 of each 14-day cycle. Administer fluorouracil and leucovorin on Day 2 as recommended. (2.1)
- Adjuvant Treatment: Continue treatment for up to 12 cycles or unacceptable toxicity. (2.1)
- Advanced Colorectal Cancer: Continue treatment until disease progression or unacceptable toxicity. (2.1)
2.1 Recommended Dosage
2.1 Recommended Dosage Administer oxaliplatin injection in combination with fluorouracil and leucovorin every 2 weeks.
- For adjuvant treatment, continue treatment for up to 12 cycles or unacceptable toxicity.
- For advanced colorectal cancer, continue treatment until disease progression or unacceptable toxicity. Day 1 Administer oxaliplatin injection 85 mg/m 2 as an intravenous infusion over 120 minutes and leucovorin 200 mg/m 2 as an intravenous infusion over 120 minutes at the same time in separate bags, followed by fluorouracil 400 mg/m 2 as intravenous bolus over 2 to 4 minutes, followed by fluorouracil 600 mg/m 2 as a 22-hour continuous infusion. Day 2 Administer leucovorin 200 mg/m 2 as an intravenous infusion over 120 minutes, followed by fluorouracil 400 mg/m 2 as intravenous bolus over 2 to 4 minutes, followed by fluorouracil 600 mg/m 2 as a 22-hour continuous infusion. Refer to the prescribing information for fluorouracil and leucovorin for additional information.
2.2 Dose Modifications for Adverse Reactions
2.2 Dose Modifications for Adverse Reactions Prolongation of infusion time for oxaliplatin injection from 2 hours to 6 hours may mitigate acute toxicities, such as non-life-threatening infusion-related reactions. Permanently discontinue oxaliplatin injection for any of the following:
- Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
- Posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.4)]
- Confirmed interstitial lung disease or pulmonary fibrosis [see Warnings and Precautions (5.5)]
- Rhabdomyolysis [see Warnings and Precautions (5.8)] Refer to the fluorouracil and leucovorin prescribing information for dosage modifications for adverse reactions. Dosage Modifications for Adjuvant Treatment Dosage modifications for adverse reactions for adjuvant treatment are presented in Table 1. Table 1: Dosage Modifications for Adjuvant Treatment in Patients with Stage III Colon Cancer Adverse Reactions Severity Oxaliplatin Injection Dosage Modifications Peripheral Sensory Neuropathy [see Warnings and Precautions (5.2)] Persistent Grade 2 Consider reducing oxaliplatin injection dose to 75 mg/m 2. Persistent Grade 3 Consider discontinuing oxaliplatin injection. Grade 4 Discontinue oxaliplatin injection. Myelosuppression [see Warnings and Precautions (5.3), Adverse Reactions (6.1)]. Grade 4 neutropenia or febrile neutropenia Delay the next dose until neutrophils greater than or equal to 1.5 × 10 9 /L and platelets greater than or equal to 75 × 10 9 /L. Reduce oxaliplatin injection dose to 75 mg/m 2. Grade 3 to 4 thrombocytopenia Gastrointestinal Adverse Reactions [see Adverse Reactions (6.1)] Grade 3 to 4 After recovery, reduce oxaliplatin injection dose to 75 mg/m 2 along with a dose reduction of fluorouracil to 300 mg/m 2 as an intravenous bolus and 500 mg/m 2 as a 22-hour continuous infusion. Dosage Modifications for Advanced Colorectal Cancer Dosage modifications for adverse reactions for advanced colorectal cancer are presented in Table 2. Table 2: Dosage Modifications for Advanced Colorectal Cancer Adverse Reactions Severity Oxaliplatin Injection Dosage Modifications Neuropathy [see Warnings and Precautions (5.2)] Persistent Grade 2 Consider reducing oxaliplatin injection dose to 65 mg/m 2. Persistent Grade 3 Consider discontinuing oxaliplatin injection. Grade 4 Discontinue oxaliplatin injection. Myelosuppression [see Warnings and Precautions (5.3), Adverse Reactions (6.1)] Grade 4 neutropenia or febrile neutropenia Delay the next dose until neutrophils greater than or equal to 1.5 × 10 9 /L and platelets greater than or equal to 75 × 10 9 /L. Reduce oxaliplatin injection dose to 65 mg/m 2. Grade 3 to 4 thrombocytopenia Gastrointestinal Adverse Reactions [see Adverse Reactions (6.1)] Grade 3 to 4 After recovery, reduce oxaliplatin injection dose to 65 mg/m 2 along with a dose reduction of fluorouracil to 300 mg/m 2 as an intravenous bolus and 500 mg/m 2 as a 22-hour continuous infusion.
2.3 Dose Modifications for Patients with Renal Impairment
2.3 Dose Modifications for Patients with Renal Impairment In patients with severe renal impairment (creatinine clearance [CLcr] less than 30 mL/min, calculated by the Cockcroft-Gault equation), reduce the oxaliplatin injection dose to 65 mg/m 2 [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].
2.4 Preparation and Administration
2.4 Preparation and Administration Oxaliplatin is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Do not freeze. Protect the concentrated solution from light. Dilute concentrated solution with 250 to 500 mL of 5% Dextrose Injection, USP. Do not dilute with sodium chloride solution or other chloride-containing solutions.
Store diluted solution for no more than 6 hours at room temperature (20°C to 25°C [68°F to 77°F]) or 24 hours under refrigeration (2°C to 8°C [36°F to 46°F]). Protection from light is not required. Visually inspect for particulate matter and discoloration prior to administration and discard if present. Do not mix oxaliplatin injection or administer oxaliplatin injection through the same infusion line concurrently with alkaline medications or media (such as basic solutions of fluorouracil).
Flush the infusion line with 5% Dextrose Injection, USP prior to administration of any concomitant medication. Do not use needles or intravenous administration sets containing aluminum parts for the preparation or mixing of oxaliplatin injection. Aluminum has been reported to cause degradation of platinum compounds. Administer oxaliplatin injection as an intravenous infusion over 120 minutes concurrently with leucovorin over 120 minutes in separate bags.
Dosing: Altered kidney function
2.3 Dose Modifications for Patients with Renal Impairment In patients with severe renal impairment (creatinine clearance [CLcr] less than 30 mL/min, calculated by the Cockcroft-Gault equation), reduce the oxaliplatin injection dose to 65 mg/m 2 [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].
8.6 Patients with Renal Impairment The AUC of unbound platinum in plasma ultrafiltrate was increased in patients with renal impairment [see Clinical Pharmacology (12.3)]. No dose reduction is recommended for patients with mild (creatinine clearance 50 to 79 mL/min) or moderate (creatinine clearance 30 to 49 mL/min) renal impairment, calculated by Cockcroft-Gault equation. Reduce the dose of oxaliplatin in patients with severe renal impairment (creatinine clearance less than 30 mL/min) [see Dosage and Administration (2.3)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of oxaliplatin in pediatrics have not been established. Safety and effectiveness were assessed across 4 open-label studies in 235 patients aged 7 months to 22 years with solid tumors. In a multicenter, open-label, non-comparative, non-randomized study (ARD5531), oxaliplatin was administered to 43 patients with refractory or relapsed malignant solid tumors, mainly neuroblastoma and osteosarcoma.
The dose limiting toxicity (DLT) was sensory neuropathy at a dose of 110 mg/m 2. The main adverse reactions were: paresthesia (60%, grade 3 to 4: 7%), fever (40%, grade 3 to 4: 7%), and thrombocytopenia (40%, grade 3 to 4: 27%). No responses were observed. In an open-label non-randomized study (DFI7434), oxaliplatin was administered to 26 pediatric patients with metastatic or unresectable solid tumors, mainly neuroblastoma and ganglioneuroblastoma.
The DLT was sensory neuropathy at a dose of 160 mg/m 2. No responses were observed. In an open-label, single-agent study (ARD5021), oxaliplatin was administered to 43 pediatric patients with recurrent or refractory embryonal CNS tumors. The most common adverse reactions reported were: leukopenia (67%, grade 3 to 4: 12%), anemia (65%, grade 3 to 4: 5%), thrombocytopenia (65%, grade 3 to 4: 26%), vomiting (65%, grade 3 to 4: 7%), neutropenia (58%, grade 3 to 4: 16%), and sensory neuropathy (40%, grade 3 to 4: 5%).
In an open-label single-agent study (ARD5530), oxaliplatin was administered to 123 pediatric patients with recurrent solid tumors, including neuroblastoma, osteosarcoma, Ewing sarcoma or peripheral PNET, ependymoma, rhabdomyosarcoma, hepatoblastoma, high grade astrocytoma, brain stem glioma, low grade astrocytoma, malignant germ cell tumor and other tumors. The most common adverse reactions reported were: sensory neuropathy (52%, grade 3 to 4: 12%), thrombocytopenia (37%, grade 3 to 4: 17%), anemia (37%, grade 3 to 4: 9%), vomiting (26%, grade 3 to 4: 4%), increased ALT (24%, grade 3 to 4: 6%), increased AST (24%, grade 3 to 4: 2%), and nausea (23%, grade 3 to 4: 3%).
The pharmacokinetic parameters of ultrafiltrable platinum were evaluated in 105 pediatric patients during the first cycle. The mean clearance in pediatric patients estimated by the population pharmacokinetic analysis was 4.7 L/h (%CV, 41%). Mean platinum pharmacokinetic parameters in ultrafiltrate were Cmax of 0.75 ± 0.24 mcg/mL, AUC0-48h of 7.52 ± 5.07 mcg∙h/mL and AUCinf of 8.83 ± 1.57 mcg.h/mL at 85 mg/m 2 of oxaliplatin and Cmax of 1.10 ± 0.43 mcg/mL, AUC0-48h of 9.74 ± 2.52 mcg.h/mL and AUCinf of 17.3 ± 5.34 mcg.h/mL at 130 mg/m 2 of oxaliplatin.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use In the adjuvant treatment trial [see Clinical Studies (14.1)], 400 patients who received oxaliplatin with fluorouracil/leucovorin were greater than or equal to 65 years. The effect of oxaliplatin in patients greater than or equal to 65 years was not conclusive. Patients greater than or equal to 65 years receiving oxaliplatin experienced more diarrhea and grade 3 to 4 neutropenia (45% vs 39%) compared to patients less than 65 years.
In the previously untreated advanced colorectal cancer trial [see Clinical Studies (14.2)], 99 patients who received oxaliplatin with fluorouracil and leucovorin were greater than or equal to 65 years. The same efficacy improvements in response rate, time to tumor progression, and overall survival were observed in the greater than or equal to 65 years patients as in the overall study population.
Adverse reactions were similar in patients less than 65 and greater than or equal to 65 years, but older patients may have been more susceptible to diarrhea, dehydration, hypokalemia, leukopenia, fatigue, and syncope. In the previously treated advanced colorectal cancer trial [see Clinical Studies (14.3)], 55 patients who received oxaliplatin with fluorouracil and leucovorin were greater than or equal to 65 years.
No overall differences in effectiveness were observed between these patients and younger adults. Adverse reactions were similar in patients less than 65 and greater than or equal to 65 years, but older patients may have been more susceptible to diarrhea, dehydration, hypokalemia, and fatigue. No significant effect of age on the clearance of ultrafiltrable platinum has been observed [see Clinical Pharmacology (12.3)].
Administration
2.2 Dose Modifications for Adverse Reactions Prolongation of infusion time for oxaliplatin injection from 2 hours to 6 hours may mitigate acute toxicities, such as non-life-threatening infusion-related reactions. Permanently discontinue oxaliplatin injection for any of the following: • Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] • Posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.4) ] • Confirmed interstitial lung disease or pulmonary fibrosis [see Warnings and Precautions (5.5) ] • Rhabdomyolysis [see Warnings and Precautions (5.8) ] Refer to the fluorouracil and leucovorin prescribing information for dosage modifications for adverse reactions. Dosage Modifications for Adjuvant Treatment Dosage modifications for adverse reactions for adjuvant treatment are presented in Table 1. Table 1: Dosage Modifications for Adjuvant Treatment in Patients with Stage III Colon Cancer Adverse Reactions Severity Oxaliplatin Injection Dosage Modifications Peripheral Sensory Neuropathy [see Warnings and Precautions (5.2) ] Persistent Grade 2 Consider reducing oxaliplatin injection dose to 75 mg/m 2 . Persistent Grade 3 Consider discontinuing oxaliplatin injection. Grade 4 Discontinue oxaliplatin injection. Myelosuppression [see Warnings and Precautions (5.3) , Adverse Reactions (6.1) ]. Grade 4 neutropenia or febrile neutropenia Delay the next dose until neutrophils greater than or equal to 1.5 × 10 9 /L and platelets greater than or equal to 75 × 10 9 /L. Reduce oxaliplatin injection dose to 75 mg/m 2 . Grade 3 to 4 thrombocytopenia Gastrointestinal Adverse Reactions [see Adverse Reactions (6.1) ] Grade 3 to 4 After recovery, reduce oxaliplatin injection dose to 75 mg/m 2 along with a dose reduction of fluorouracil to 300 mg/m 2 as an intravenous bolus and 500 mg/m 2 as a 22-hour continuous infusion. Dosage Modifications for Advanced Colorectal Cancer Dosage modifications for adverse reactions for advanced colorectal cancer are presented in Table 2. Table 2: Dosage Modifications for Advanced Colorectal Cancer Adverse Reactions Severity Oxaliplatin Injection Dosage Modifications Neuropathy [see Warnings and Precautions (5.2) ] Persistent Grade 2 Consider reducing oxaliplatin injection dose to 65 mg/m 2 . Persistent Grade 3 Consider discontinuing oxaliplatin injection. Grade 4 Discontinue oxaliplatin injection. Myelosuppression [see Warnings and Precautions (5.3) , Adverse Reactions (6.1) ] Grade 4 neutropenia or febrile neutropenia Delay the next dose until neutrophils greater than or equal to 1.5 × 10 9 /L and platelets greater than or equal to 75 × 10 9 /L. Reduce oxaliplatin injection dose to 65 mg/m 2 . Grade 3 to 4 thrombocytopenia Gastrointestinal Adverse Reactions [see Adverse Reactions (6.1) ] Grade 3 to 4 After recovery, reduce oxaliplatin injection dose to 65 mg/m 2 along with a dose reduction of fluorouracil to 300 mg/m 2 as an intravenous bolus and 500 mg/m 2 as a 22-hour continuous infusion.
2.4 Preparation and Administration Oxaliplatin is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Do not freeze. Protect the concentrated solution from light. Dilute concentrated solution with 250 to 500 mL of 5% Dextrose Injection, USP. Do not dilute with sodium chloride solution or other chloride-containing solutions. Store diluted solution for no more than 6 hours at room temperature (20°C to 25°C [68°F to 77°F]) or 24 hours under refrigeration (2°C to 8°C [36°F to 46°F]). Protection from light is not required. Visually inspect for particulate matter and discoloration prior to administration and discard if present. Do not mix oxaliplatin injection or administer oxaliplatin injection through the same infusion line concurrently with alkaline medications or media (such as basic solutions of fluorouracil). Flush the infusion line with 5% Dextrose Injection, USP prior to administration of any concomitant medication. Do not use needles or intravenous administration sets containing aluminum parts for the preparation or mixing of oxaliplatin injection. Aluminum has been reported to cause degradation of platinum compounds. Administer oxaliplatin injection as an intravenous infusion over 120 minutes concurrently with leucovorin over 120 minutes in separate bags.
US FDA labelDosage forms
Philippines
- ) solution for injection: 2 mg/mL (100 mg/5 mL, 2 mg/mL (100 mg/50 mL, 2 mg/mL (50 mg/25 mL, 5 mg/mL (100 mg/20 mL, 5 mg/mL (50 mg/10 mL, 5 mg/mL (50 mg/mL
- ) concentrate solution for iv infusion: 2 mg/mL (100 mg/5 mL, 2 mg/mL (100 mg/50 mL, 2 mg/mL (50 mg/25 mL
- Lyophilized powder for injection: 50 mg, 100 mg
- Lyophilized powder for iv infusion: 50 mg
- ) solution for iv infusion: 2 mg/mL (100 mg/50 mL, 2 mg/mL (50 mg/25 mL, 5 mg/mL (50 mg/10 mL) and (100 mg/20 mL
- Concentrate solution for injection: 2 mg/mL
- Powder for solution for iv infusion: 50 mg, 100 mg
- ) concentrate solution for i.v. infusion: 5 mg/mL (100 mg/20 mL, 5 mg/mL (50 mg/10 mL
- Concentrate for solution for infusion: 5 mg/mL
- Lyophilized powder for injection for i.v. infusion: 50 mg, 100 mg
and 16 more forms; see the products table.
Registered products in the Philippines
88 products registered with the Food and Drug Administration (FDA) Philippines list Oxaliplatin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products88
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Aplixatin-100Oxaliplatin | 2 mg/mL (100mg/50 mL) Concentrate Solution for IV Infusion50 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Detoxicare Phils., Inc.Importer: Ambica International Corporation | DRP-10165 | Oct 20, 2031 | |
Aplixatin-50Oxaliplatin | 2 mg/mL (50mg/25 mL) Concentrate Solution for IV Infusion30 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Detoxicare Phils., Inc.Importer: Ambica International Corporation | DRP-10166 | Oct 6, 2031 | |
BaplatinOxaliplatin | 100 mg Lyophilized Powder for Solution for Infusion (IV)50 mL USP Type II amber glass vial with halobutyl rubber stopper and white flip-off aluminium seal Box of 1's | RxVAT-exempt | Laboratorio Kemex S.A.Argentine Republic | Apolloplus Capital Inc.Trader: Bioprofarma Bago S.A. | DR-XY46429 | Sep 28, 2028 | |
BaplatinOxaliplatin | 50 mg Lyophilized Powder for Solution for Infusion (IV)25 mL USP Type I amber glass vial with halobutyl rubber stopper and royal-blue flip-off aluminium seal (Box of 1's) | RxVAT-exempt | Laboratorio Kemex S.A.Argentine Republic | Apolloplus Capital Inc.Trader: Bioprofarma Bago S.A. | DR-XY46428 | Sep 28, 2028 | |
CeldachOxaliplatin | 100 mg Lyophilized Powder for solution for I.V InfusionUSP Type I Clear Glass Vial with Grey Bromobutyl Rubber Stopper with Red Color Flip-off seal x 50 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E Medica Inc. | DRP-2367 | Jul 30, 2030 | |
CeldachOxaliplatin | 50mg Lyophilized Power for Solution for I.V InfusionUSP Type I Clear tubular glass vial with grey bromobutyl rubber stopper with red color flip-off seal x 30mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E. Medica, Inc. | DRP-2365 | Jul 30, 2031 | |
ColorebeneOxaliplatin | 100 mg Lyophilized Powder for Solution for I.V. InfusionUSP Type I Clear Glass Vial with Grey Bromobutyl Rubber Stopper with Red Color Flip-off Seal x 50 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E Medica Inc. | DRP-2367-01 | Feb 20, 2031 | |
ColorebeneOxaliplatin | 50 mg Lyophilized Powder for Solution for I.V. InfusionUSP Type l Clear Tubular Glass Vial with Grey Bromobutyl Rubber Stopper with Red Color Flip-off Seal x 30 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E Medica Inc. | DRP-2365-01 | Jun 13, 2031 | |
ColoxOxaliplatin | 50 mg Lyophilized Powder for Injection (IV Infusion)30 mL-capacity Type I glass vial with gray bromobutyl rubber stopper and blue aluminum-plastic flip-off cap (Box of 1's) | RxVAT-exempt | Cisen Pharmaceutical Co. Ltd.China | Macropharma Corporation | DRP-15871 | Sep 25, 2029 | |
ColoxatinOxaliplatin | 100 mg Lyophilized Powder for Injection (I.V. Infusion)USP Type I clear colorless glass vial (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals Ltd.India | Accord Healthcare Limited - Philippine Branch OfficeImporter: Oncolife Corporation | DRP-7193-01 | Jan 19, 2027 | |
DoxatinOxaliplatin | 50 mg Lyophilized Powder for Injection (IV Infusion)30 mL-capacity colorless transparent borosilicate glass vial sealed with rubber stopper and blue aluminum plastic cap (1 vial/box; each carton contains 100 boxes) | RxVAT-exempt | Cisen Pharmaceutical Co., Ltd.China | Endure Medical, Inc. | DR-XY48985 | Jan 25, 2029 | |
EloxaOxaliplatin | 5mg/ mL (50 mg/10 mL & 100 mg/20 mL) Concentrate For Solution For I.V. InfusionUSP Type I Clear Glass Vial with Bromo butyl Rubber Stopper and Flip- off Aluminum Seal Cap x 10 mL & 20 mL (Box of 1's) | RxVAT-exempt | Qilu Pharmaceutical (Hainan) Co. Ltd.China | Macropharma Corporation | DRP-18407 | Jul 2, 2031 | |
EloxatinOxaliplatin | 5 mg/mL Concentrate for Solution for Infusion (IV)Type I Colorless Glass Vial x 10 mL (equivalent to 50 mg) Box of 1's; Type I Colorless Glass Vial x 20 mL (equivalent to 100 mg) Box of 1's; Type I Colorless Glass Vial x 40 mL (equivalent to 200 mg) Box of 1's | RxVAT-exempt | Sanofi-Aventis Deutschland GmbHGermany | Importer: Sanofi-Aventis Philippines Inc. | DR-XY32998 | Oct 9, 2029 | |
Emiplatin-100Oxaliplatin | 2 mg/mL (100 mg/50 mL) Solution for Injection (IV Infusion)USP Type I Amber Glass Vial x 50 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-8426-04 | Sep 13, 2028 | |
Emiplatin-50Oxaliplatin | 2 mg / mL (50 mg/ 25 mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 30 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-8699-04 | Sep 12, 2028 | |
Fin- Oxali 50Oxaliplatin | 5 mg/mL (50 mg/10 mL) Solution for Injection (I.V.)10 mL-net content USP Type I amber glass vial with bromobutyl rubber plug and aluminum seal polypropylene flip-off cap (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Finstad, Inc. | DRP-14908 | Feb 7, 2029 | |
FlucinOxaliplatin | 100 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11224-01 | Feb 15, 2027 | |
FlucinOxaliplatin | 50 mg Lyophilized Powder for IV Infusion50 mL USP Type I Clear Glass Vial with Gray Bromo Butyl Rubber Stopper, Aluminum Cap and Blue Flip-off Seal (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11004-01 | Dec 31, 2026 | |
GenplatinOxaliplatin | 100 mg Lyophilized Powder for Injection (IV Infusion)50mL Type I Transparent Colorless Glass Vial Sealed with Gray Rubber Stopper and Aluminum Seal with PP Cap x 1's (Box of 1's) | RxVAT-exempt | Chong Kun Dang Pharmaceutical Corp.Republic of Korea | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc | DRP-12596-01 | Sep 12, 2027 | |
HenplatinOxaliplatin | 50 mg Lyophilized Powder for Injection (IV)USP Type I Neutral Borosilicate Glass Vial with 20 mm Rubber Stopper and Aluminum Plastic Cap x 20 mL (Box of 1’s) | RxVAT-exempt | Jiangsu-Hengrui Pharmaceutical Co., Ltd.China | Goodfellow Pharma Corporation | DR-XY32620 | Jun 9, 2037 | |
InnoxaplinOxaliplatin | 2 mg/mL (50 mg/25 mL) Concentrate Solution for IV Infusion30 mL-capacity USP Type I Amber Moulded Glass Vial x 25 mL with Bromobutyl Rubber Stopper and Green Flip-off Seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Innocure Pharma and Medical Supplies TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-8887-01 | Jul 2, 2030 | |
Innoxaplin 100Oxaliplatin | 2 mg/mL (100 mg/5 mL) Concentrate Solution for IV InfusionUSP Type I Amber Molded Glass Vial x 50 mL with bromobutyl rubber stopper and green flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Innocure Pharma and Medical Supplies TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-8888-01 | Jul 2, 2030 | |
LealoxaliOxaliplatin | 2 mg / mL (50 mg / 25 mL) Concentrate Solution for IV Infusion30 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Lealmeds Pharmaceutical Inc.Importer: Ambica International Corporation | DRP-10166-02 | Oct 6, 2031 | |
LealoxaliOxaliplatin | 2 mg/mL (100mg/50 mL) Concentrate Solution for IV Infusion50 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Lealmeds Pharmaceutical Inc.Importer: Ambica International Corporation | DRP-10165-02 | Oct 6, 2031 | |
LipanoxOxaliplatin | 2 mg/mL Concentrate Solution for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 10 mL and 20 mL (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Kaufmann Pharma Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11225-01 | Feb 15, 2027 | |
MeslatinOxaliplatin | 100 mg Lyophilized Powder for Injection (I.V. Infusion)USP Type I Clear Colorless Glass Vial (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Oncolife Corporation | DR-XY40552 | Jan 19, 2027 | |
MeslatinOxaliplatin | 50 mg Lyophilized Powder for Injection (IV Infusion)USP Type I Clear Colorless Glass Vial (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Oncolife Corporation | DRP-8219 | Jan 24, 2027 | |
NoneOxaliplatin | 2 mg/mL (100 mg/50 mL) Solution for Injection (IV)Type I Amber Moulded Glass Vial x 50 mL (Box of 1's) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-5174-01 | Feb 13, 2029 | |
NoneOxaliplatin | 5 mg/mL (100mg/20mL) Solution for Injection (IV Infusion)20 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and flip-off cap (Box of 1's) | RxVAT-exempt | Alwin DMD PharmaceuticalsIndia | Amediqo Phils., Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15506-01 | Jul 30, 2029 | |
NoneOxaliplatin | 5 mg/mL Concentrate for Solution for IV InfusionUSP Type I Clear Glass Vial x 10 mL and 20 mL with rubber stopper and green (for 10 mL) or dark blue (for 20 mL) flip-off seal (Box of 1's) | RxVAT-exempt | Zydus Hospira Oncology Pvt. Ltd.India | Importer: Pfizer, Inc. | DR-XY45870 | May 9, 2027 | |
NovaplatinOxaliplatin | 100 mg Lyophilized Powder for Injection (IV Infusion)50 mL Type I Transparent Colorless Glass Vial Sealed with Gray Rubber Stopper and Aluminum Seal with PP Cap x l's (Box of 1's) | RxVAT-exempt | Chong Kun Dang Pharmaceutical Corp.Korea | Medinova Pharmaceutical, Inc. | DRP-12596 | Sep 12, 2027 | |
NovaplatinOxaliplatin | 50 mg Lyophilized Powder for Injection (IV Infusion)40 mL-capacity Type I Clear and Colorless Glass Vial Sealed with Grey Rubber Stopper, Aluminum Seal and Green Polypropylene Flip-off Cap x 1's (Box of 1's) | RxVAT-exempt | Chong Kun Dang Pharmaceutical Corp.Korea | Medinova Pharmaceutical Inc. | DRP-17072 | Sep 19, 2030 | |
Oxa-Health 100Oxaliplatin | 2 mg/mL (100 mg/50 mL) Solution for Injection (IV Infusion)USP Type I Amber Glass Vial x 50 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8426-01 | Sep 13, 2028 | |
Oxa-Health 50Oxaliplatin | 2 mg/mL (50 mg/25 mL) Solution for InjectionUSP Type I Amber Glass Vial x 30 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8699-01 | Sep 12, 2028 | |
OxadexcelOxaliplatin | 100 mg Powder for Solution for IV Infusion50 mL amber vial with elastomeric rubber stopper and aluminum crimp cap with plastic flip-off (Box of 1's) | RxVAT-exempt | Glenmark Generics S.A.Argentine Republic | One Dexcel Pharma Inc.Importer: Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Limited | DRP-8101-01 | Sep 23, 2037 | |
OxadexcelOxaliplatin | 50 mg Powder for Solution for IV Infusion25 mL amber vial with elastomeric rubber stopper and aluminum crimp cap with plastic flip-off (Box of 1's) | RxVAT-exempt | Glenmark Generics S.A.Argentine Republic | One Dexcel Pharma, Inc.Importer: Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Limited | DRP-8102-01 | Oct 26, 2037 | |
OXAL SPAL-L 100Oxaliplatin | 5 mg/mL (100 mg/20 mL) Solution For InfusionUSP Type I clear and colorless glass vial with grey chlorobutyl rubber stopper and parrot green aluminum- polypropylene flip-off seal x 20 mL (Box of 1's) | RxVAT-exempt | SP Accure Labs Pvt. Ltd.India | Hexagon Pharmaceuticals | DRP-15869 | Sep 25, 2029 | |
OxaleeOxaliplatin | 100 mg Lyophilized Powder for I.V. InfusionType I Clear Colorless Glass Vial (Box of 1's) | RxVAT-exempt | Laboratorios Richmond S.A.C.I.F.Argentine Republic | UNILAB, Inc. | DR-XY40362 | Nov 29, 2031 | |
OxaleeOxaliplatin | 50 mg Lyophilized Powder For IV InfusionType I Clear Colorless Glass Vial (Box of 1's) | RxVAT-exempt | Laboratorios Richmond S.A.C.I.F.Argentina | UNILAB, Inc. | DR-XY40361 | Nov 29, 2026 | |
OxalibilOxaliplatin | 5 mg/ mL (100 mg/20 mL) Concentrate for Solution for Intravenous (IV) InfusionUSP Type I clear glass vial x 20 mL (Box of l's) | RxVAT-exempt | SP Accure Labs Pvt. Ltd.India | Hexagon Pharmaceuticals | DR-XY48264 | Aug 9, 2027 | |
OxalidexOxaliplatin | 5 mg/mL Concentrate for Solution for InfusionType I Colorless Glass Vial with Grey Halobutyl Rubber Stopper and Aluminum Crimp Cap (10 mL; 20 mL; 40 mL) (Box of 1's) | RxVAT-exempt | Fareva Unterach GmbHAustria | Delex Pharma International, Inc.Importer: Sandoz Philippines Corporation | DRP-8254-01 | Jul 16, 2029 | |
OxaligetOxaliplatin | 2 mg/mL (100 mg/50 mL) Solution for IV InfusionType I Amber glass vial x 50 mL with rubber stopper and aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | 2mg Incorporated | DRP-16259 | Jan 10, 2030 | |
OxaligetOxaliplatin | 2 mg/mL (100mg/50 mL) Concentrate Solution for IV Infusion50 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | 2MG IncorporatedImporter: Ambica International Corporation | DRP-10165-01 | Oct 20, 2037 | |
OxaligetOxaliplatin | 2 mg/mL (50 mg/25 mL) Solution for IV Infusion.Type I amber glass vial x 25 mL in 30 mL with rubber. stopper and aluminum black flip-off seal (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | 2MG Incorporated | DRP-15430 | Jul 8, 2029 | |
OxaliGetOxaliplatin | 2 mg/mL (50mg/25 mL) Concentrate Solution for IV Infusion30 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | 2MG IncorporatedImporter: Ambica International Corporation | DRP-10166-01 | Sep 12, 2037 | |
OxaliplaceenOxaliplatin | 2 mg / mL (50 mg/25 mL) Concentrate Solution for IV InfusionUSP Type I Amber glass vial with bromobutyl rubber stopper and green flip-off seal x 25 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Noble Pharma Inc.Importer: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Private Limited | DRP-11973-02 | May 26, 2027 | |
OxaliqoOxaliplatin | 5 mg / mL (50 mg / mL) Solution for Injection (IV Infusion)10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | RxVAT-exempt | Alwin DMD PharmaceuticalsIndia | Amediqo Phils., Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15507-01 | Jul 30, 2029 | |
Oxalis 100Oxaliplatin | 5 mg/mL (100 mg/20mL) Solution for Injection (IV Infusion)20 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and flip-off cap (Box of 1's) | RxVAT-exempt | Alwin DMD PharmaceuticalsIndia | Bliss Pharma Distribution and Consultancy Corp. | DRP-15506 | Jul 30, 2029 | |
Oxalis 50Oxaliplatin | 5 mg/mL (50 mg/10mL) Solution for Injection (IV Infusion)10 mL USP type I amber glass vial with vial with bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | RxVAT-exempt | Alwin DMD PharmaceuticalsIndia | Bliss Pharma Distribution and Consultancy Corp. | DRP-15507 | Jul 30, 2029 | |
OxalitinOxaliplatin | 5 mg/mL Solution for Injection for IV use10 mL USP Type I colorless glass vial Box of 1's and 10's; 20 mL USP Type I colorless glass vial Box of 1's and 10's | RxVAT-exempt | Boryung Pharamaceutical Co., Ltd.Republic of Korea | Endure Medical Inc. | DR-XY46143 | Nov 2, 2027 | |
Oxalivid 100Oxaliplatin | 100 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I Colorless glass vial with 20 mm brominated butyl rubber stopper and blue 20 mm aluminum plastic cap Box of 1's | RxVAT-exempt | Qilu Pharmaceutical (Hainan) Co., Ltd.China | Hovid, Inc.Trader: Hovid Bhd. | DR-XY47098 | Oct 28, 2030 | |
Oxalivid 50Oxaliplatin | 50 mg Lyophilized Powder for Injection for IV InfusionUSP Type I Colorless Glass Vial with 20 mm Brominated Butyl Rubber Stopper and Blue 20 mm Aluminum Plastic Cap (Box of 1's) | RxVAT-exempt | Qilu Pharmacetical Hainan Co., Ltd.China | Hovid Inc.Importer: Hovid IncTrader: Hovid Bhd. | DR-XY47099 | Oct 29, 2030 | |
Oxalotin 50Oxaliplatin | 50 mg Lyophilized Powder for IV InfusionUSP Type I Clear Glass Vial x 50 mL Box of 1's | RxVAT-exempt | TECHNO DRUGS LIMITEDBangladesh | BRIDGEMARK MARKETING | DR-XY43225 | Feb 25, 2028 | |
OxaltinOxaliplatin | 5 mg/mL (50 mg/10 mL and 100 mg/20 mL) Concentrate Solution for Intravenous InjectionUSP Type I clear and colorless glass vial x 10 mL and 20 mL (Box of 1’s) | RxVAT-exempt | Jiangsu Hengrui Pharmaceuticals Co., Ltd.China | Phil. Pharmawealth, Inc. | DR-XY47591 | Dec 9, 2031 | |
OxambaOxaliplatin | 50 mg Lyophilized Powder for IV Infusion30 mL-capacity USP Type I clear glass vial, with grey butyl rubber stopper, aluminum seal, and flip-off cap (Box of 1's) | RxVAT-exempt | Cisen Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-16119 | Nov 6, 2029 | |
Oxanish-100Oxaliplatin | 2 mg/mL (100 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Amber Glass Vial x 50 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-8426 | Sep 13, 2028 | |
Oxanish-50Oxaliplatin | 2 mg/mL (50mg/25mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 30 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-8699 | Sep 12, 2028 | |
OxaplatOxaliplatin | 50 mg. Lyophilized Powder for Injection (I.V. Infusion)USP Type I Amber Glass Bottle (Box of 1's) | RxVAT-exempt | Eriochem S.A.Argentina | Importer: Globo Asiatico Enterprises, Inc. | DR-XY34088 | Dec 27, 2027 | |
OxariOxaliplatin | 2 mg / mL (50 mg / 25 mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 30 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Oncotine Pharmaceutical Products DistributionImporter: Pharmastar Int'l Trading Corp. | DRP-8699-03 | Sep 12, 2028 | |
OxasaphOxaliplatin | 50 mg Lyophilized Powder for IV Infusion50 mL USP Type I clear glass vial with gray bromo butyl rubber stopper, aluminum cap and blue flip-off seal (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, IncTrader: Sapphire Lifesciences Pvt. Ltd. | DRP-11004 | Dec 31, 2026 | |
Oxasaph-100Oxaliplatin | 100 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11224 | Feb 15, 2027 | |
Oxasaph-2Oxaliplatin | 2 mg/mL Concentrate Solution For Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 10 mL, 20 mL, 25 mL and 50 mL (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11225 | Dec 27, 2027 | |
OxawindOxaliplatin | 2 mg/mL (100mg/50mL) Solution for Injection (IV Infusion)USP Type I Amber Glass Vial x 50 mL (Box of 1's) | RxVAT-exempt | ADMAC LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8426-03 | Sep 13, 2028 | |
OxawindOxaliplatin | 2 mg/mL (50 mg/25 mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 30 mL (Box of 1's) | RxVAT-exempt | ADMAC LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8699-02 | Sep 12, 2028 | |
OxAyos-100Oxaliplatin | 2 mg/mL (100 mg/50 mL) Solution for IV InfusionType I amber glass vial x 50 mL with rubber stopper and aluminum flip-off seal (Box of 1’s) | RxVAT-exempt | Venus Remedies, LimitedIndia | Getmeds Philippines Inc.Importer: 2mg Incorporated | DRP-16259-01 | Jan 10, 2030 | |
OxAyos-50Oxaliplatin | 2 mg/mL (50 mg/25mL) Solution for IV InfusionType I amber glass vial x 25 mL in 30 mL with rubber stopper and aluminum black flip-off seal (Box of 1’s) | RxVAT-exempt | Venus Remedies, LimitedIndia | Getmeds Philippines Inc.Importer: 2mg Incorporated | DRP-15430-01 | Jul 8, 2029 | |
OxitelOxaliplatin | 5 mg/mL (50 mg/10 mL) and (100 mg/20 mL) Solution for IV Infusion10 mL (net content) USP Type I clear and colorless glass vial (Box of 1 vial); 20 mL (net content) USP Type I clear and colorless glass vial (Box of 1 vial) | RxVAT-exempt | Fresenius Kabi Oncology LimitedIndia | Fresenius Kabi Philippines Inc. | DR-XY47603 | Dec 13, 2028 | |
OxubaOxaliplatin | 100 mg Powder for Solution for IV Infusion50 mL amber vial with elastomeric rubber stopper and aluminum crimp cap with plastic flip-off Box of 1's | RxVAT-exempt | Glenmark Generics S.A.Argentine Republic | Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Limited | DRP-8101 | Mar 16, 2037 | |
OxubaOxaliplatin | 50 mg Powder for Solution for IV Infusion25 mL amber vial with elastomeric rubber stopper and aluminum crimp cap with plastic flip-off (Box of 1's) | RxVAT-exempt | Glenmark Generics S.A.Argentine Republic | Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Limited | DRP-8102 | Mar 6, 2037 | |
OxzaritineOxaliplatin | 2 mg/ mL (50 mg/ 25 mL) Concentrate Solution for IV InfusionUSP Type I Amber glass vial with bromobutyl rubber stopper and green flip-off seal x 25 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Oncotine Pharmaceutical Products DistributionImporter: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-11973-01 | May 26, 2027 | |
PlatinoxOxaliplatin | 100 mg Lyophilized Powder For Injection (I.V. Infusion)100 mL-capacity USP Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with blue plastic flip-off cap (box of vial) | RxVAT-exempt | Korea United Pharm. Inc.Korea | Qualimed Pharma, Inc. | DR-XY47656 | Jan 7, 2027 | |
PlatinoxOxaliplatin | 50 mg Lyophilized Powder for IV InfusionClear, colorless glass vial Box of 1's | RxVAT-exempt | Korea United Pharm., Inc.Republic of Korea | Qualimed Pharma Inc. | DR-XY35406 | Feb 4, 2029 | |
PlatixelOxaliplatin | 5mg/mL Concentrate for Solution For I.V. Infusion20 mL-capacity Type I colorless glass vial with teflon chlorobutyl rubber stopper and aluminum cap (Box of 1 vial x 10 mL; Box of 1 vial x 20 mL) | RxVAT-exempt | Sichuan Huiyu Pharmaceutical Company LimitedChina | Oncolife Corporation | DR-XY48273 | Aug 15, 2027 | |
PlaxatinOxaliplatin | 50 mg Lyophilized Powder for Injection for I.V. InfusionType I medium boron silicon glass tube-type vial sealed with pharmaceutical bromo butyl rubber stopper (Box of 1's) | RxVAT-exempt | Jari Pharmaceutical Co., Ltd.People's Republic of China | AMB HK ENTERPRISES INC. | DRP-10590 | Oct 20, 2031 | |
RextaOxaliplatin | 5 mg/mL (100 mg / 20 mL) Concentrate Solution for I.V. Infusion20 mL (net content) Type 1 clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with white polypropylene flip-off cap (Box of 1's) | RxVAT-exempt | PT. Global Onkolab FarmaIndonesia | Globo Asiatico Enterprises, Inc.Trader: Kalbe International Pte. Ltd. | DR-XY48686 | Mar 31, 2031 | |
RextaOxaliplatin | 5 mg/mL (50 mg/10 mL) Concentrate Solution for I.V. Infusion10mL (net content) Type 1 clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with white polypropylene flip-off cap (Box of 1's) | RxVAT-exempt | PT Global Onkolab FarmaIndonesia | Globo Asiatico Enterprises, Inc.Trader: Kalbe International Pte. Ltd. | DR-XY48687 | Mar 31, 2031 | |
Staloxa-100Oxaliplatin | 2 mg/mL (100 mg/50 mL) Concentrate Solution for IV Infusion50 mL-capacity USP Type I Amber Moulded Glass Vial x 50 mL with bromobutyl rubber stopper and green flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Multi Product Line Pharma, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-8888 | Jul 2, 2030 | |
Staloxa-50Oxaliplatin | 2 mg/mL (50 mg/25 mL) Concentrate Solution for IV Infusion30 mL-capacity USP Type I Amber Moulded Glass Vial x 25 mL with bromobutyl rubber stopper and green flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Multi Product Line Pharma, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-8887 | Jul 2, 2030 | |
UketOxaliplatin | 2 mg/mL Concentrate Solution for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 50 mL (Box of 1’s) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11225-03 | Feb 15, 2027 | |
UketOxaliplatin | 2 mg/mL Concentrate Solution for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 25 mL (Box of 1’s) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11225-04 | Feb 15, 2027 | |
Unioxali 100Oxaliplatin | 2 mg/mL (100 mg/50 mL) Concentrate Solution for IV InfusionUSP Type I Amber glass vial with bromobutyl rubber stopper and green flip-off seal x 50 mL (Box of 1’s) | RxVAT-exempt | Admac LifesciencesIndia | Pharma 518, Inc.Importer: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-11974 | May 26, 2032 | |
Unioxali 50Oxaliplatin | 2 mg/mL (50 mg/25 mL) Concentrate Solution for IV InfusionUSP Type I Amber glass vial with bromobutyl rubber stopper and green flip-off seal x 25 mL (Box of 1’s) | RxVAT-exempt | Admac LifesciencesIndia | Pharma 518, Inc.Importer: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-11973 | May 26, 2037 | |
Vexplatin VE-100Oxaliplatin | 5 mg/mL (100 mg/20 mL) Solution for Injection (IV Infusion)Type I Amber Colored Glass Vial with Bromobutyl Flurocoated Rubber Stopper and Aluminum PP Flip-Off Cap x 20 mL (Box of 1’s) | RxVAT-exempt | Venus Remedies LimitedIndia | VE Pharma, Inc.Trader: Vexxa Lifesciences Pvt. Ltd | DRP-10856 | Dec 9, 2031 | |
Vexplatin Ve-50Oxaliplatin | 5 mg/mL (50 mg/10 mL) Solution for Injection (IV Infusion)Type I Amber Colored Glass Vial with Bromobutyl Flurocoated Rubber Stopper and Aluminum PP Flip Off Cap x 10 mL (Box of 1’s) | RxVAT-exempt | Venus Remedies LimitedIndia | VE Pharma, Inc.Trader: Vexxa Lifesciences Pvt. Ltd | DRP-10857 | Dec 9, 2031 | |
Vexplatin-100Oxaliplatin | 2 mg/mL ( 100 mg/50 mL) Solution for I.V InfusionUSP Type I Amber Glass Vial x 50 mL (50 mL as Net Content) (Box of 1’s) | RxVAT-exempt | Admac LifesciencesIndia | VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY44380 | Mar 26, 2030 | |
Vexplatin-50Oxaliplatin | 2 mg/mL (50 mg/25 mL) Solution for I.V. InfusionUSP Type I Amber Glass Vial x 30 mL (25 mL as net content) Box of 1’s | RxVAT-exempt | ADMAC LifesciencesIndia | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY44379 | Mar 26, 2030 | |
XalipatOxaliplatin | 2 mg/mL (100 mg/50 mL) Solution for Injection (iv)Type I Amber Moulded Glass Vial x 50 mL (Box of 1's) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Medethix, Inc. | DRP-5174 | Feb 13, 2029 | |
Zildox 50Oxaliplatin | 50 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial (Box of 1's) | RxVAT-exempt | Naprod Lifesciences Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc. | DRP-2905 | Aug 24, 2032 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: 50 mg (5 mg/mL), 100 mg (5 mg/mL) or 200 mg (5 mg/mL) clear, colorless solution in a single-dose vial. Injection: 50 mg (5 mg/mL), 100 mg (5 mg/mL) or 200 mg (5 mg/mL) in a single-dose vial (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Peripheral Sensory Neuropathy: Acute and delayed neuropathy can occur. Avoid topical application of ice. Reduce the dose or permanently discontinue oxaliplatin as recommended. (5.2)
- Severe Myelosuppression: Delay oxaliplatin until neutrophils are greater than or equal to 1.5 × 10 9 /L and platelets are greater than or equal to 75 × 10 9 /L. Withhold oxaliplatin for sepsis or septic shock. Dose reduce after recovery from grade 4 neutropenia, febrile neutropenia, or grade 3 to 4 thrombocytopenia as recommended. (5.3)
- Posterior Reversible Encephalopathy Syndrome (PRES): Permanently discontinue oxaliplatin in patients who develop PRES. (5.4)
- Pulmonary Toxicity: Withhold oxaliplatin until investigation excludes interstitial lung disease or pulmonary fibrosis. (5.5)
- Hepatotoxicity: Monitor liver function tests at baseline, before each subsequent cycle, and as clinically indicated. (5.6)
- QT Interval Prolongation: Avoid in patients with congenital long QT syndrome. Monitor electrocardiograms in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Correct electrolyte abnormalities prior to initiating oxaliplatin and periodically during treatment. (5.7)
- Rhabdomyolysis: Permanently discontinue oxaliplatin if rhabdomyolysis occurs. (5.8)
- Hemorrhage: Increase frequency …
5.1 Hypersensitivity Reactions
5.1 Hypersensitivity Reactions Serious and fatal hypersensitivity reactions, including anaphylaxis, can occur with oxaliplatin within minutes of administration and during any cycle. Grade 3 to 4 hypersensitivity reactions, including anaphylaxis, occurred in 2% to 3% of patients with colon cancer who received oxaliplatin.
Hypersensitivity reactions, including rash, urticaria, erythema, pruritus, and rarely, bronchospasm and hypotension, were similar in nature and severity to those reported with other platinum-based drugs. Oxaliplatin is contraindicated in patients with hypersensitivity reactions to platinum-based drugs [see Contraindications (4)].
Immediately and permanently discontinue oxaliplatin for hypersensitivity reactions and administer appropriate treatment for management of hypersensitivity reactions.
5.2 Peripheral Sensory Neuropathy
5.2 Peripheral Sensory Neuropathy Oxaliplatin can cause acute and delayed neuropathy. Reduce the dose or permanently discontinue oxaliplatin for persistent neurosensory reactions based on the severity of the adverse reaction [see Dosage and Administration (2.2)]. Acute Neuropathy Acute neuropathy typically presents as a reversible, primarily peripheral sensory neuropathy that occurs within hours or 2 days following a dose, resolves within 14 days, and frequently recurs with further dosing.
The symptoms can be precipitated or exacerbated by exposure to cold temperature or cold objects and they usually present as transient paresthesia, dysesthesia and hypoesthesia in the hands, feet, perioral area, or throat. Jaw spasm, abnormal tongue sensation, dysarthria, eye pain, and a feeling of chest pressure have also been observed.
The acute, reversible pattern of sensory neuropathy was observed in about 56% of patients who received oxaliplatin with fluorouracil/leucovorin. In any individual cycle, acute neuropathy occurred in approximately 30% of patients. For grade 3 peripheral sensory neuropathy, the median time to onset was 9 cycles for adjuvant treatment and 6 cycles for previously treated advanced colorectal cancer.
An acute syndrome of pharyngolaryngeal dysesthesia occurred in 1% to 2% (grade 3 to 4) of patients previously untreated for advanced colorectal cancer. Subjective sensations of dysphagia or dyspnea, without any laryngospasm or bronchospasm (no stridor or wheezing) occurred in patients previously treated for advanced colorectal cancer.
Avoid topical application of ice for mucositis prophylaxis or other conditions, because cold temperature can exacerbate acute neurological symptoms. Delayed Neuropathy Delayed neuropathy typically presents as a persistent (greater than 14 days), primarily peripheral sensory neuropathy that is usually characterized by paresthesias, dysesthesias, and hypoesthesias, but may also include deficits in proprioception that can interfere with daily activities (e.g., writing, buttoning, swallowing, and difficulty walking from impaired proprioception).
These forms of neuropathy occurred in 48% of patients receiving oxaliplatin. Delayed neuropathy can occur without any prior acute neuropathy. Most patients (80%) who developed grade 3 persistent neuropathy progressed from prior grade 1 or 2 reactions. These symptoms may improve in some patients upon discontinuation of oxaliplatin.
Adjuvant treatment In the adjuvant treatment trial, neuropathy was graded using NCI CTC, version 1 as summarized in Table 3. Table 3: Grading for Neuropathy in Adjuvant Treatment Trial Grade Definition 0 No change or none 1 Mild paresthesias, loss of deep tendon reflexes 2 Mild or moderate objective sensory loss, moderate paresthesias 3 Severe objective sensory loss or paresthesias that interfere with function 4 Not applicable Peripheral sensory neuropathy occurred in 92% of patients (all grades), including 13% of patients (grade 3) who received oxaliplatin with fluorouracil/leucovorin.
At the 28-day follow-up after the last treatment cycle, 60% of patients had any grade (grade 1=40%, grade 2=16%, grade 3=5%) peripheral sensory neuropathy, decreasing to 39% at 6 months of follow-up (grade 1=31%, grade 2=7%, grade 3=1%) and 21% at 18 months of follow-up (grade 1=17%, grade 2=3%, grade 3=1%). Advanced colorectal cancer In the advanced colorectal cancer trials, neuropathy was graded using the neurotoxicity scale summarized in Table 4.
Table 4: Grading for Neuropathy in Advanced Colorectal Cancer Trials Grade Definition 1 Resolved and did not interfere with functioning 2 Interfered with function but not daily activities 3 Pain or functional impairment that interfered with daily activities 4 Persistent impairment that is disabling or life-threatening Neuropathy occurred in 82% (all grades) of patients previously untreated for advanced colorectal cancer, including 19% grade 3 to 4; and in 74% (all grades) of patients previously treated for advanced colorectal cancer, including 7% grade 3 to 4.
5.3 Severe Myelosuppression
5.3 Severe Myelosuppression Grade 3 or 4 neutropenia occurred in 41% to 44% of patients with colorectal cancer who received oxaliplatin with fluorouracil/leucovorin. Sepsis, neutropenic sepsis and septic shock, including fatal outcomes, occurred in patients who received oxaliplatin [see Adverse Reactions (6.1, 6.2)]. Grade 3 or 4 thrombocytopenia occurred in 2% to 5% of patients with colorectal cancer who received oxaliplatin with fluorouracil/leucovorin.
Monitor complete blood cell count at baseline, before each subsequent cycle and as clinically indicated. Delay oxaliplatin until neutrophils are greater than or equal to 1.5 × 10 9 /L and platelets are greater than or equal to 75 × 10 9 /L. Withhold oxaliplatin for sepsis or septic shock. Dose reduce oxaliplatin after recovery from grade 4 neutropenia, febrile neutropenia or grade 3 to 4 thrombocytopenia as recommended [see Dosage and Administration (2.2)].
5.4 Posterior Reversible Encephalopathy Syndrome
5.4 Posterior Reversible Encephalopathy Syndrome PRES occurred in less than 0.1% of patients across clinical trials [see Adverse Reactions (6.1)]. Signs and symptoms of PRES can include headache, altered mental functioning, seizures, abnormal vision from blurriness to blindness, associated or not with hypertension. Confirm the diagnosis of PRES with magnetic resonance imaging.
Permanently discontinue oxaliplatin in patients who develop PRES.
5.5 Pulmonary Toxicity
5.5 Pulmonary Toxicity Oxaliplatin has been associated with pulmonary fibrosis (less than 1% of patients), which may be fatal [see Adverse Reactions (6.1)]. In the adjuvant treatment trial, the combined incidence of cough and dyspnea was 7.4% (any grade), including less than 1% (grade 3) in the oxaliplatin arm. One patient died from eosinophilic pneumonia in the oxaliplatin arm.
In the previously untreated advanced colorectal cancer trial, the combined incidence of cough, dyspnea and hypoxia was 43% (any grade), including 7% (grade 3 to 4) in the oxaliplatin with fluorouracil/leucovorin arm. In case of unexplained respiratory symptoms, such as non-productive cough, dyspnea, crackles, or radiological pulmonary infiltrates, withhold oxaliplatin until further pulmonary investigation excludes interstitial lung disease or pulmonary fibrosis.
Permanently discontinue oxaliplatin for confirmed interstitial lung disease or pulmonary fibrosis.
5.6 Hepatotoxicity
5.6 Hepatotoxicity In the adjuvant treatment trial, increased transaminases (57% vs 34%) and alkaline phosphatase (42% vs 20%) occurred more commonly in the oxaliplatin arm than in the fluorouracil/leucovorin arm [see Adverse Reactions (6.1)]. The incidence of increased bilirubin was similar on both arms. Changes noted on liver biopsies include: peliosis, nodular regenerative hyperplasia or sinusoidal alterations, perisinusoidal fibrosis, and veno-occlusive lesions.
Consider evaluating patients who develop abnormal liver tests or portal hypertension, which cannot be explained by liver metastases, for hepatic vascular disorders. Monitor liver function tests at baseline, before each subsequent cycle, and as clinically indicated.
5.7 QT Interval Prolongation and Ventricular Arrhythmias
5.7 QT Interval Prolongation and Ventricular Arrhythmias QT prolongation and ventricular arrhythmias, including fatal torsade de pointes, have been reported with oxaliplatin [see Adverse Reactions (6.2)]. Avoid oxaliplatin in patients with congenital long QT syndrome. Monitor electrocardiograms (ECG) in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities and in patients taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics [see Drug Interactions (7.1)].
Monitor and correct electrolyte abnormalities prior to initiating oxaliplatin and periodically during treatment.
5.8 Rhabdomyolysis
5.8 Rhabdomyolysis Rhabdomyolysis, including fatal cases, has been reported with oxaliplatin [see Adverse Reactions (6.2)]. Permanently discontinue oxaliplatin for any signs or symptoms of rhabdomyolysis.
5.9 Hemorrhage
5.9 Hemorrhage The incidence of hemorrhage in clinical trials was higher on the oxaliplatin combination arm compared to the fluorouracil/leucovorin arm. These reactions included gastrointestinal bleeding, hematuria, and epistaxis. In the adjuvant treatment trial, 2 patients died from intracerebral hemorrhage [see Adverse Reactions (6.1)].
Prolonged prothrombin time and INR occasionally associated with hemorrhage have been reported in patients who received oxaliplatin with fluorouracil/leucovorin while on anticoagulants [see Adverse Reactions (6.2)]. Increase frequency of monitoring in patients who are receiving oxaliplatin with fluorouracil/leucovorin and oral anticoagulants [see Drug Interactions (7.3)].
Thrombocytopenia and immune-mediated thrombocytopenia have been observed with oxaliplatin. Rapid onset of thrombocytopenia and greater risk of bleeding have been observed in immune-mediated thrombocytopenia. In this case, consider discontinuing oxaliplatin.
5.10 Embryo-Fetal Toxicity
5.10 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, oxaliplatin can cause fetal harm when administered to a pregnant woman. The available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of oxaliplatin. Reproductive toxicity studies demonstrated adverse effects on embryo-fetal development in rats at maternal doses that were below the recommended human dose based on body surface area.
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with oxaliplatin and for 9 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with oxaliplatin and for 6 months after the final dose [see Use in Specific Populations (8.1, 8.3)].
Drug interactions
7.1 Drugs
7.1 Drugs that Prolong the QT Interval QT interval prolongation and ventricular arrhythmias can occur with oxaliplatin [see Warnings and Precautions (5.7)]. Avoid coadministration of oxaliplatin with medicinal products with a known potential to prolong the QT interval.
7.2 Use with Nephrotoxic Products
7.2 Use with Nephrotoxic Products Because platinum-containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds [see Clinical Pharmacology (12.3)]. Avoid coadministration of oxaliplatin with medicinal products known to cause nephrotoxicity.
7.3 Use with Anticoagulants
7.3 Use with Anticoagulants Prolonged prothrombin time and INR occasionally associated with hemorrhage have been reported in patients who received oxaliplatin with fluorouracil/leucovorin while on anticoagulants [see Warnings and Precautions (5.9), Adverse Reactions (6.2)]. Increase frequency of monitoring in patients who are receiving oxaliplatin with fluorouracil/leucovorin and oral anticoagulants.
Adverse reactions
- The following clinically significant adverse reactions are described elsewhere in labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Peripheral Sensory Neuropathy [see Warnings and Precautions (5.2)] Severe Myelosuppression [see Warnings and Precautions (5.3)] Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.4)] Pulmonary Toxicity [see Warnings and Precautions (5.5)] Hepatotoxicity [see Warnings and Precautions (5.6)] QT Interval Prolongation and Ventricular Arrhythmias [see Warnings and Precautions (5.7)] Rhabdomyolysis [see Warnings and Precautions (5.8)] Hemorrhage [see Warnings and Precautions (5.9)] Most common adverse reactions (incidence greater than or equal to 40%) were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue, and stomatitis. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Gland Pharma at 864-879-9994 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. More than 1100 patients with stage II or III colon cancer and more than 4,000 patients with advanced colorectal cancer were treated in trials with oxaliplatin.
The most common adverse reactions in patients with stage II or III colon cancer receiving adjuvant treatment were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue and stomatitis. The most common adverse reactions in previously untreated and treated patients with advanced colorectal cancer were peripheral sensory neuropathies, fatigue, neutropenia, nausea, emesis, and diarrhea.
Adjuvant Treatment The safety of oxaliplatin in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in patients with stage II or III colon cancer, who had undergone complete resection of the primary tumor in the adjuvant treatment trial [see Clinical Studies (14.1)]. Fatal adverse reactions in patients who received oxaliplatin in the combination arm included sepsis/neutropenic sepsis (n=3), intracerebral hemorrhage (n=2), and eosinophilic pneumonia (n=1).
Thromboembolic events occurred in 6% (grade 3 to 4, 1.2%) of patients in the oxaliplatin arm. Grade 3 or 4 adverse reactions occurred in 70% of patients in the oxaliplatin arm. Grade 3 to 4 gastrointestinal bleeding occurred in 0.2% of patients. Febrile neutropenia occurred in 0.7% and documented infection with concomitant grade 3 to 4 neutropenia occurred in 1.1%.
Discontinuation due to an adverse reaction occurred in 15% of the patients in the oxaliplatin arm. Tables 5, 6, and 7 summarize the adverse reactions reported in patients with colon cancer receiving adjuvant treatment. Table 5: Adverse Reactions Reported in Patients with Colon Cancer Receiving Adjuvant Treatment (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=1108 FU/LV N=1111 All Grades (%) Grade 3 to 4 (%) All Grades (%) Grade 3 to 4 (%) Neurology Peripheral Sensory Neuropathy 92 12 16 <1 Gastrointestinal Nausea 74 5 61 2 Diarrhea 56 11 48 7 Vomiting 47 6 24 1 Stomatitis 42 3 40 2 Anorexia 13 1 8 <1 Constitutional Symptoms/Pain Fatigue 44 4 38 1 Abdominal Pain 18 1 17 2 Dermatology/Skin Skin Disorder 32 2 36 2 Injection Site Reaction † 11 3 10 3 Fever/Infection Fever 27 1 12 1 Infection 25 4 25 3 Allergy/Immunology Allergic Reaction 10 3 2 <1 * Event coded in WHO-ART dictionary † Includes thrombosis related to the catheter Table 6: Adverse Reactions Reported in Patients with Colon Cancer Receiving Adjuvant Treatment (greater than or equal to 5% of all patients but with less than 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=1108 FU/LV N=1111 All Grades (%) All Grades (%) Dermatology/Skin Alopecia † 30 28 Gastrointestinal Constipation 22 19 Taste Perversion 12 8 Dyspepsia 8 5 Constitutional Symptoms/Pain/Ocular/Visual Epistaxis 16 12 Weight Increase 10 10 Conjunctivitis 9 15 Headache 7 5 Dyspnea 5 3 Pain 5 5 Abnormal Lacrimation 4 12 Neurology Sensory Disturbance 8 1 Allergy/Immunology Rhinitis 6 8 * Event coded in WHO-ART dictionary † No complete alopecia was reported In females, the following grade 3 to 4 adverse reactions were more frequent: diarrhea, fatigue, neutropenia, nausea, and vomiting.
In patients greater than or equal to 65 years old, the incidence of grade 3 to 4 diarrhea and neutropenia was higher than in younger adults. Clinically relevant adverse reactions were reported in greater than or equal to 2% and less than 5% of the patients in the oxaliplatin arm (listed in decreasing order of frequency) were pain, leukopenia, weight loss, and cough.
Table 7: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients with Colon Cancer Receiving Adjuvant Treatment Laboratory-Related Adverse Reaction Oxaliplatin with FU/LV N=1108 FU/LV N=1111 All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) Hematology Neutropenia 79 41 40 5 Thrombocytopenia 77 2 19 <1 Anemia 76 1 67 <1 Hepatic Increased Transaminases 57 2 34 1 Increased Alkaline Phosphatase 42 <1 20 <1 Hyperbilirubinemia 20 4 20 5 Previously Untreated Advanced Colorectal Cancer The safety of oxaliplatin in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a randomized trial of patients with previously untreated advanced colorectal cancer [see Clinical Studies (14.2)]. The adverse reaction profile in this trial was similar to that seen in other trials.
Tables 8, 9, and 10 summarize the adverse reactions reported in the previously untreated advanced colorectal cancer trial. Table 8: Adverse Reactions Reported in Patients in the Previously Untreated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=259 Irinotecan + FU/LV N=256 Oxaliplatin + Irinotecan N=258 All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) Neurology Neuropathy 82 19 18 2 69 7 Paresthesias 77 18 16 2 62 6 Pharyngo-laryngeal Dysesthesias 38 2 1 0 28 1 Neuro-sensory 12 1 2 0 9 1 Neuro NOS † 1 0 1 0 1 0 Gastrointestinal Nausea 71 6 67 15 83 19 Diarrhea 56 12 65 29 76 25 Vomiting 41 4 43 13 64 23 Stomatitis 38 0 25 1 19 1 Anorexia 35 2 25 4 27 5 Constipation 32 4 27 2 21 2 Diarrhea-colostomy 13 2 16 7 16 3 Gastrointestinal NOS † 5 2 4 2 3 2 Constitutional Symptoms/Pain/Ocular/Visual Fatigue 70 7 58 11 66 16 Abdominal Pain 29 8 31 7 39 10 Myalgia 14 2 6 0 9 2 Pain 7 1 5 1 6 1 Abnormal Vision 5 0 2 1 6 1 Neuralgia 5 0 0 0 2 1 Pulmonary Cough 35 1 25 2 17 1 Dyspnea 18 7 14 3 11 2 Hiccups 5 1 2 0 3 2 Hepatic/Metabolic/Laboratory/Renal Hyperglycemia 14 2 11 3 12 3 Hypokalemia 11 3 7 4 6 2 Dehydration 9 5 16 11 14 7 Hypoalbuminemia 8 0 5 2 9 1 Hyponatremia 8 2 7 4 4 1 Urinary Frequency 5 1 2 1 3 1 Hematology/Infection Infection Normal ANC ‡ 10 4 5 1 7 2 Infection Low ANC ‡ 8 8 12 11 9 8 Lymphopenia 6 2 4 1 5 2 Febrile Neutropenia 4 4 15 14 12 11 Dermatology/Skin Hand/Foot Syndrome 7 1 2 1 1 0 Injection Site Reaction 6 0 1 0 4 1 Cardiovascular Thrombosis 6 5 6 6 3 3 Hypotension 5 3 6 3 4 3 * Event coded in WHO-ART dictionary † Not otherwise specified ‡ Absolute neutrophil count Table 9: Adverse Reactions Reported in Patients in the Previously Untreated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients but with less than 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=259 Irinotecan + FU/LV N=256 Oxaliplatin + Irinotecan N=258 All Grades (%) All Grades (%) All Grades (%) Dermatology/Skin Alopecia † 38 44 67 Flushing 7 2 5 Pruritus 6 4 2 Dry Skin 6 2 5 Hematology/Infection Fever Normal ANC ‡ 16 9 9 Cardiovascular Edema 15 13 10 Gastrointestinal Taste Perversion 14 6 8 Dyspepsia 12 7 5 Flatulence 9 6 5 Mouth Dryness 5 2 3 Constitutional Symptoms/Pain/Ocular/Visual Headache 13 6 9 Weight Loss 11 9 11 Epistaxis 10 2 2 Tearing 9 1 2 Rigors 8 2 7 Dysphasia 5 3 3 Sweating 5 6 12 Arthralgia 5 5 8 Neurology Insomnia 13 9 11 Depression 9 5 7 Dizziness 8 6 10 Anxiety 5 2 6 Allergy/Immunology Rash 11 4 7 Rhinitis Allergic 10 6 6 Hepatic/Metabolic/Laboratory/Renal Hypocalcemia 7 5 4 Elevated Creatinine 4 4 5 * Event coded in WHO-ART dictionary † No complete alopecia was reported ‡ Absolute neutrophil count Clinically relevant adverse reactions that occurred in greater than or equal to 2% and less than 5% of the patients in the oxaliplatin and fluorouracil/leucovorin combination arm (listed in decreasing order of frequency) were: metabolic, pneumonitis, catheter infection, vertigo, prothrombin time, pulmonary, rectal bleeding, dysuria, nail changes, chest pain, rectal pain, syncope, hypertension, hypoxia, unknown infection, bone pain, pigmentation changes, and urticaria.
Table 10: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients in the Previously Untreated Advanced Colorectal Cancer Trial Laboratory-Related Adverse Reaction Oxaliplatin and FU/LV N=259 Irinotecan and FU/LV N=256 Oxaliplatin and Irinotecan N=258 All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) Hematology Leukopenia 85 20 84 23 76 24 Neutropenia 81 53 77 44 71 36 Thrombocytopenia 71 5 26 2 44 4 Anemia 27 3 28 4 25 3 Hepatic Increased AST* 17 1 2 1 11 1 Increased Alkaline Phosphatase 16 0 8 0 14 2 Hyperbilirubinemia 6 1 3 1 3 2 Increased ALT † 6 1 2 0 5 2 * Aspartate transaminase † Alanine transaminase Previously Treated Advanced Colorectal Cancer The safety of oxaliplatin in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a randomized trial in patients with refractory and relapsed colorectal cancer [see Clinical Studies (14.3)]. The adverse reaction profile in this trial was similar to that seen in other trials.
Three patients who received oxaliplatin in the combination arm experienced fatal adverse reactions: gastrointestinal bleeding and dehydration. Grade 3 and 4 neutropenia were reported in 27% and 17% of patients, respectively, in the oxaliplatin with fluorouracil/leucovorin combination arm. Grade 3 to 4 increased serum creatinine occurred in 1% of patients in the oxaliplatin with combination fluorouracil/leucovorin arm.
Thirteen percent of patients in the oxaliplatin with fluorouracil/leucovorin combination arm discontinued treatment; the most frequent reasons were gastrointestinal adverse reactions, hematologic adverse reactions and neuropathies. Tables 11, 12, and 13 summarize the adverse reactions reported in the previously treated advanced colorectal cancer trial.
Table 11: Adverse Reactions Reported in Patients in the Previously Treated Advanced Colorectal Cancer Trial (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=150 Oxaliplatin N=153 FU/LV N=142 All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) Neurology Neuropathy 74 7 76 7 17 0 Acute 56 2 65 5 10 0 Persistent 48 6 43 3 9 0 Constitutional Symptoms/Pain Fatigue 68 7 61 9 52 6 Back Pain 19 3 11 0 16 4 Pain 15 2 14 3 9 3 Gastrointestinal Diarrhea 67 11 46 4 44 3 Nausea 65 11 64 4 59 4 Vomiting 40 9 37 4 27 4 Stomatitis 37 3 14 0 32 3 Abdominal Pain 33 4 31 7 31 5 Anorexia 29 3 20 2 20 1 Gastroesophageal Reflux 5 2 1 0 3 0 Hematology/Infection Fever 29 1 25 1 23 1 Febrile Neutropenia 6 6 0 0 1 1 Cardiovascular Dyspnea 20 4 13 7 11 2 Coughing 19 1 11 0 9 0 Edema 15 1 10 1 13 1 Thromboembolism 9 8 2 1 4 2 Chest Pain 8 1 5 1 4 1 Dermatology/Skin Injection Site Reaction 10 3 9 0 5 1 Hepatic/Metabolic/Laboratory/Renal Hypokalemia 9 4 3 2 3 1 Dehydration 8 3 5 3 6 4 * Event coded in WHO-ART dictionary Table 12: Adverse Reactions Reported in Patients in the Previously Treated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients but with less than 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=150 Oxaliplatin N=153 FU/LV N=142 All Grades (%) All Grades (%) All Grades (%) Gastrointestinal Constipation 32 31 23 Dyspepsia 14 7 10 Taste Perversion 13 5 1 Mucositis 7 2 10 Flatulence 5 3 6 Constitutional Symptoms/Pain/Ocular/Visual Headache 17 13 8 Arthralgia 10 7 10 Epistaxis 9 2 1 Abnormal Lacrimation 7 1 6 Rigors 7 9 6 Allergy/Immunology Rhinitis 15 6 4 Allergic Reaction 10 3 1 Rash 9 5 5 Neurology Dizziness 13 7 8 Insomnia 9 11 4 Dermatology/Skin Hand-Foot Syndrome 11 1 13 Flushing 10 3 2 Alopecia † 7 3 3 Pulmonary Upper Respiratory Tract Infection 10 7 4 Pharyngitis 9 2 10 Cardiovascular Peripheral Edema 10 5 11 Hepatic/Metabolic/Laboratory/Renal Hematuria 6 0 4 Dysuria 6 1 1 * Event coded in WHO-ART dictionary † No complete alopecia was reported Clinically relevant adverse reactions in greater than or equal to 2% and less than 5% of the patients in the oxaliplatin and fluorouracil/leucovorin combination arm (listed in decreasing order of frequency) were: anxiety, myalgia, erythematous rash, increased sweating, conjunctivitis, weight decrease, dry mouth, rectal hemorrhage, depression, ataxia, ascites, hemorrhoids, muscle weakness, nervousness, tachycardia, abnormal micturition frequency, dry skin, pruritus, hemoptysis, purpura, vaginal hemorrhage, melena, somnolence, pneumonia, proctitis, involuntary muscle contractions, intestinal obstruction, gingivitis, tenesmus, hot flashes, enlarged abdomen, and urinary incontinence. Table 13: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients with Previously Treated Advanced Colorectal Cancer Laboratory-Related Adverse Reaction Oxaliplatin and FU/LV N=150 Oxaliplatin N=153 FU/LV N=142 All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) Hematology Anemia 81 2 64 1 68 2 Leukopenia 76 19 13 0 34 1 Neutropenia 73 44 7 0 25 5 Thrombocytopenia 64 4 30 3 20 0 Hepatic Increased ALT * 31 0 36 1 28 3 Increased AST † 47 0 54 4 39 2 Increased Bilirubin 13 1 13 5 22 6 * Alanine transaminase † Aspartate transaminase Additional Adverse Reactions The following adverse reactions were observed across clinical trials.
Intravenous site reactions Injection site reaction, including redness, swelling, and pain, can occur with oxaliplatin. In some cases, skin necrosis has occurred with extravasation. PRES PRES occurred in less than 0.1% of patients. Pulmonary fibrosis and interstitial lung disease Pulmonary fibrosis, which may be fatal, occurred in less than 1% of patients.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of oxaliplatin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
General: angioedema, anaphylactic shock Cardiovascular: QT prolongation leading to ventricular arrhythmias, including fatal torsade de pointes; bradyarrhythmia Neurological: loss of deep tendon reflexes, dysarthria, Lhermitte’s sign, cranial nerve palsies, fasciculations, convulsion Hearing and vestibular system: deafness Infections: septic shock, including fatal outcomes Infusion-related reactions and hypersensitivity reactions: laryngospasm Hepatic and gastrointestinal: severe diarrhea/vomiting resulting in hypokalemia, colitis (including Clostridium difficile diarrhea), metabolic acidosis, ileus, intestinal obstruction, pancreatitis, sinusoidal obstruction syndrome, perisinusoidal fibrosis which rarely may progress, focal nodular hyperplasia, esophagitis Musculoskeletal and connective tissue: rhabdomyolysis, including fatal outcomes Platelet, bleeding, and clotting disorders: immuno-allergic thrombocytopenia, prolonged prothrombin time and INR in patients receiving anticoagulants Blood disorders: secondary leukemia Red blood cell: hemolytic uremic syndrome, immuno-allergic hemolytic anemia Renal: acute tubular necrosis, acute interstitial nephritis, acute renal failure Respiratory: interstitial lung diseases (sometimes fatal) and pneumonia (including fatal outcomes) Vision: decrease of visual acuity, visual field disturbance, optic neuritis and transient vision loss (reversible following treatment discontinuation) Injury, poisoning, and procedural complications: fall-related injuries
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reaction* | Oxaliplatin + FU/LV N=1108 | FU/LV N=1111 | ||
| All Grades (%) | Grade 3 to 4 (%) | All Grades (%) | Grade 3 to 4 (%) | |
| Neurology | ||||
| Peripheral Sensory Neuropathy | 92 | 12 | 16 | <1 |
| Gastrointestinal | ||||
| Nausea | 74 | 5 | 61 | 2 |
| Diarrhea | 56 | 11 | 48 | 7 |
| Vomiting | 47 | 6 | 24 | 1 |
| Stomatitis | 42 | 3 | 40 | 2 |
| Anorexia | 13 | 1 | 8 | <1 |
| Constitutional Symptoms/Pain | ||||
| Fatigue | 44 | 4 | 38 | 1 |
| Abdominal Pain | 18 | 1 | 17 | 2 |
| Dermatology/Skin | ||||
| Skin Disorder | 32 | 2 | 36 | 2 |
| Injection Site Reaction† | 11 | 3 | 10 | 3 |
| Fever/Infection | ||||
| Fever | 27 | 1 | 12 | 1 |
| Infection | 25 | 4 | 25 | 3 |
| Allergy/Immunology | ||||
| Allergic Reaction | 10 | 3 | 2 | <1 |
| Adverse Reaction* | Oxaliplatin + FU/LV N=1108 | FU/LV N=1111 |
| All Grades (%) | All Grades (%) | |
| Dermatology/Skin | ||
| Alopecia† | 30 | 28 |
| Gastrointestinal | ||
| Constipation | 22 | 19 |
| Taste Perversion | 12 | 8 |
| Dyspepsia | 8 | 5 |
| Constitutional Symptoms/Pain/Ocular/Visual | ||
| Epistaxis | 16 | 12 |
| Weight Increase | 10 | 10 |
| Conjunctivitis | 9 | 15 |
| Headache | 7 | 5 |
| Dyspnea | 5 | 3 |
| Pain | 5 | 5 |
| Abnormal Lacrimation | 4 | 12 |
| Neurology | ||
| Sensory Disturbance | 8 | 1 |
| Allergy/Immunology | ||
| Rhinitis | 6 | 8 |
| Laboratory-Related Adverse Reaction | Oxaliplatin with FU/LV N=1108 | FU/LV N=1111 | ||
| All Grades (%) | Grades 3 to 4 (%) | All Grades (%) | Grades 3 to 4 (%) | |
| Hematology | ||||
| Neutropenia | 79 | 41 | 40 | 5 |
| Thrombocytopenia | 77 | 2 | 19 | <1 |
| Anemia | 76 | 1 | 67 | <1 |
| Hepatic | ||||
| Increased Transaminases | 57 | 2 | 34 | 1 |
| Increased Alkaline Phosphatase | 42 | <1 | 20 | <1 |
| Hyperbilirubinemia | 20 | 4 | 20 | 5 |
| Adverse Reaction* | Oxaliplatin + FU/LV N=259 | Irinotecan + FU/LV N=256 | Oxaliplatin + Irinotecan N=258 | ||||||||
| All Grades (%) | Grades 3 to 4 (%) | All Grades (%) | Grades 3 to 4 (%) | All Grades (%) | Grades 3 to 4 (%) | ||||||
| Neurology | |||||||||||
| Neuropathy | 82 | 19 | 18 | 2 | 69 | 7 | |||||
| Paresthesias | 77 | 18 | 16 | 2 | 62 | 6 | |||||
| Pharyngo-laryngeal Dysesthesias | 38 | 2 | 1 | 0 | 28 | 1 | |||||
| Neuro-sensory | 12 | 1 | 2 | 0 | 9 | 1 | |||||
| Neuro NOS† | 1 | 0 | 1 | 0 | 1 | 0 | |||||
| Gastrointestinal | |||||||||||
| Nausea | 71 | 6 | 67 | 15 | 83 | 19 | |||||
| Diarrhea | 56 | 12 | 65 | 29 | 76 | 25 | |||||
| Vomiting | 41 | 4 | 43 | 13 | 64 | 23 | |||||
| Stomatitis | 38 | 0 | 25 | 1 | 19 | 1 | |||||
| Anorexia | 35 | 2 | 25 | 4 | 27 | 5 | |||||
| Constipation | 32 | 4 | 27 | 2 | 21 | 2 | |||||
| Diarrhea-colostomy | 13 | 2 | 16 | 7 | 16 | 3 | |||||
| Gastrointestinal NOS† | 5 | 2 | 4 | 2 | 3 | 2 | |||||
| Constitutional Symptoms/Pain/Ocular/Visual | |||||||||||
| Fatigue | 70 | 7 | 58 | 11 | 66 | 16 | |||||
| Abdominal Pain | 29 | 8 | 31 | 7 | 39 | 10 | |||||
| Myalgia | 14 | 2 | 6 | 0 | 9 | 2 | |||||
| Pain | 7 | 1 | 5 | 1 | 6 | 1 | |||||
| Abnormal Vision | 5 | 0 | 2 | 1 | 6 | 1 | |||||
| Neuralgia | 5 | 0 | 0 | 0 | 2 | 1 | |||||
| Pulmonary | |||||||||||
| Cough | 35 | 1 | 25 | 2 | 17 | 1 | |||||
| Dyspnea | 18 | 7 | 14 | 3 | 11 | 2 | |||||
| Hiccups | 5 | 1 | 2 | 0 | 3 | 2 | |||||
| Hepatic/Metabolic/Laboratory/Renal | |||||||||||
| Hyperglycemia | 14 | 2 | 11 | 3 | 12 | 3 | |||||
| Hypokalemia | 11 | 3 | 7 | 4 | 6 | 2 | |||||
| Dehydration | 9 | 5 | 16 | 11 | 14 | 7 | |||||
| Hypoalbuminemia | 8 | 0 | 5 | 2 | 9 | 1 | |||||
| Hyponatremia | 8 | 2 | 7 | 4 | 4 | 1 | |||||
| Urinary Frequency | 5 | 1 | 2 | 1 | 3 | 1 | |||||
| Hematology/Infection | |||||||||||
| Infection Normal ANC‡ | 10 | 4 | 5 | 1 | 7 | 2 | |||||
| Infection Low ANC‡ | 8 | 8 | 12 | 11 | 9 | 8 | |||||
| Lymphopenia | 6 | 2 | 4 | 1 | 5 | 2 | |||||
| Febrile Neutropenia | 4 | 4 | 15 | 14 | 12 | 11 | |||||
| Dermatology/Skin | |||||||||||
| Hand/Foot Syndrome | 7 | 1 | 2 | 1 | 1 | 0 | |||||
| Injection Site Reaction | 6 | 0 | 1 | 0 | 4 | 1 | |||||
| Cardiovascular | |||||||||||
| Thrombosis | 6 | 5 | 6 | 6 | 3 | 3 | |||||
| Hypotension | 5 | 3 | 6 | 3 | 4 | 3 | |||||
| Adverse Reaction* | Oxaliplatin + FU/LV N=259 | Irinotecan + FU/LV N=256 | Oxaliplatin + Irinotecan N=258 |
| All Grades (%) | All Grades (%) | All Grades (%) | |
| Dermatology/Skin | |||
| Alopecia† | 38 | 44 | 67 |
| Flushing | 7 | 2 | 5 |
| Pruritus | 6 | 4 | 2 |
| Dry Skin | 6 | 2 | 5 |
| Hematology/Infection | |||
| Fever Normal ANC‡ | 16 | 9 | 9 |
| Cardiovascular | |||
| Edema | 15 | 13 | 10 |
| Gastrointestinal | |||
| Taste Perversion | 14 | 6 | 8 |
| Dyspepsia | 12 | 7 | 5 |
| Flatulence | 9 | 6 | 5 |
| Mouth Dryness | 5 | 2 | 3 |
| Constitutional Symptoms/Pain/Ocular/Visual | |||
| Headache | 13 | 6 | 9 |
| Weight Loss | 11 | 9 | 11 |
| Epistaxis | 10 | 2 | 2 |
| Tearing | 9 | 1 | 2 |
| Rigors | 8 | 2 | 7 |
| Dysphasia | 5 | 3 | 3 |
| Sweating | 5 | 6 | 12 |
| Arthralgia | 5 | 5 | 8 |
| Neurology | |||
| Insomnia | 13 | 9 | 11 |
| Depression | 9 | 5 | 7 |
| Dizziness | 8 | 6 | 10 |
| Anxiety | 5 | 2 | 6 |
| Allergy/Immunology | |||
| Rash | 11 | 4 | 7 |
| Rhinitis Allergic | 10 | 6 | 6 |
| Hepatic/Metabolic/Laboratory/Renal | |||
| Hypocalcemia | 7 | 5 | 4 |
| Elevated Creatinine | 4 | 4 | 5 |
| Laboratory-Related Adverse Reaction | Oxaliplatin and FU/LV N=259 | Irinotecan and FU/LV N=256 | Oxaliplatin and Irinotecan N=258 | ||||
| All Grades (%) | Grades 3 to 4 (%) | All Grades (%) | Grades 3 to 4 (%) | All Grades (%) | Grades 3 to 4 (%) | ||
| Hematology | |||||||
| Leukopenia | 85 | 20 | 84 | 23 | 76 | 24 | |
| Neutropenia | 81 | 53 | 77 | 44 | 71 | 36 | |
| Thrombocytopenia | 71 | 5 | 26 | 2 | 44 | 4 | |
| Anemia | 27 | 3 | 28 | 4 | 25 | 3 | |
| Hepatic | |||||||
| Increased AST* | 17 | 1 | 2 | 1 | 11 | 1 | |
| Increased Alkaline Phosphatase | 16 | 0 | 8 | 0 | 14 | 2 | |
| Hyperbilirubinemia | 6 | 1 | 3 | 1 | 3 | 2 | |
| Increased ALT† | 6 | 1 | 2 | 0 | 5 | 2 | |
| Adverse Reaction* | Oxaliplatin + FU/LV N=150 | Oxaliplatin N=153 | FU/LV N=142 | |||
| All Grades (%) | Grades 3 to 4 (%) | All Grades (%) | Grades 3 to 4 (%) | All Grades (%) | Grades 3 to 4 (%) | |
| Neurology | ||||||
| Neuropathy | 74 | 7 | 76 | 7 | 17 | 0 |
| Acute | 56 | 2 | 65 | 5 | 10 | 0 |
| Persistent | 48 | 6 | 43 | 3 | 9 | 0 |
| Constitutional Symptoms/Pain | ||||||
| Fatigue | 68 | 7 | 61 | 9 | 52 | 6 |
| Back Pain | 19 | 3 | 11 | 0 | 16 | 4 |
| Pain | 15 | 2 | 14 | 3 | 9 | 3 |
| Gastrointestinal | ||||||
| Diarrhea | 67 | 11 | 46 | 4 | 44 | 3 |
| Nausea | 65 | 11 | 64 | 4 | 59 | 4 |
| Vomiting | 40 | 9 | 37 | 4 | 27 | 4 |
| Stomatitis | 37 | 3 | 14 | 0 | 32 | 3 |
| Abdominal Pain | 33 | 4 | 31 | 7 | 31 | 5 |
| Anorexia | 29 | 3 | 20 | 2 | 20 | 1 |
| Gastroesophageal Reflux | 5 | 2 | 1 | 0 | 3 | 0 |
| Hematology/Infection | ||||||
| Fever | 29 | 1 | 25 | 1 | 23 | 1 |
| Febrile Neutropenia | 6 | 6 | 0 | 0 | 1 | 1 |
| Cardiovascular | ||||||
| Dyspnea | 20 | 4 | 13 | 7 | 11 | 2 |
| Coughing | 19 | 1 | 11 | 0 | 9 | 0 |
| Edema | 15 | 1 | 10 | 1 | 13 | 1 |
| Thromboembolism | 9 | 8 | 2 | 1 | 4 | 2 |
| Chest Pain | 8 | 1 | 5 | 1 | 4 | 1 |
| Dermatology/Skin | ||||||
| Injection Site Reaction | 10 | 3 | 9 | 0 | 5 | 1 |
| Hepatic/Metabolic/Laboratory/Renal | ||||||
| Hypokalemia | 9 | 4 | 3 | 2 | 3 | 1 |
| Dehydration | 8 | 3 | 5 | 3 | 6 | 4 |
| Adverse Reaction* | Oxaliplatin + FU/LV N=150 | Oxaliplatin N=153 | FU/LV N=142 |
| All Grades (%) | All Grades (%) | All Grades (%) | |
| Gastrointestinal | |||
| Constipation | 32 | 31 | 23 |
| Dyspepsia | 14 | 7 | 10 |
| Taste Perversion | 13 | 5 | 1 |
| Mucositis | 7 | 2 | 10 |
| Flatulence | 5 | 3 | 6 |
| Constitutional Symptoms/Pain/Ocular/Visual | |||
| Headache | 17 | 13 | 8 |
| Arthralgia | 10 | 7 | 10 |
| Epistaxis | 9 | 2 | 1 |
| Abnormal Lacrimation | 7 | 1 | 6 |
| Rigors | 7 | 9 | 6 |
| Allergy/Immunology | |||
| Rhinitis | 15 | 6 | 4 |
| Allergic Reaction | 10 | 3 | 1 |
| Rash | 9 | 5 | 5 |
| Neurology | |||
| Dizziness | 13 | 7 | 8 |
| Insomnia | 9 | 11 | 4 |
| Dermatology/Skin | |||
| Hand-Foot Syndrome | 11 | 1 | 13 |
| Flushing | 10 | 3 | 2 |
| Alopecia† | 7 | 3 | 3 |
| Pulmonary | |||
| Upper Respiratory Tract Infection | 10 | 7 | 4 |
| Pharyngitis | 9 | 2 | 10 |
| Cardiovascular | |||
| Peripheral Edema | 10 | 5 | 11 |
| Hepatic/Metabolic/Laboratory/Renal | |||
| Hematuria | 6 | 0 | 4 |
| Dysuria | 6 | 1 | 1 |
| Laboratory-Related Adverse Reaction | Oxaliplatin and FU/LV N=150 | Oxaliplatin N=153 | FU/LV N=142 | |||
| All Grades (%) | Grades 3 to 4 (%) | All Grades (%) | Grades 3 to 4 (%) | All Grades (%) | Grades 3 to 4 (%) | |
| Hematology | ||||||
| Anemia | 81 | 2 | 64 | 1 | 68 | 2 |
| Leukopenia | 76 | 19 | 13 | 0 | 34 | 1 |
| Neutropenia | 73 | 44 | 7 | 0 | 25 | 5 |
| Thrombocytopenia | 64 | 4 | 30 | 3 | 20 | 0 |
| Hepatic | ||||||
| Increased ALT* | 31 | 0 | 36 | 1 | 28 | 3 |
| Increased AST† | 47 | 0 | 54 | 4 | 39 | 2 |
| Increased Bilirubin | 13 | 1 | 13 | 5 | 22 | 6 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on its direct interaction with DNA, oxaliplatin can cause fetal harm when administered to a pregnant woman. The available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of oxaliplatin. Reproductive toxicity studies demonstrated adverse effects on embryo-fetal development in rats at maternal doses that were below the recommended human dose based on body surface area (see Data).
Advise a pregnant woman of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal data Pregnant rats were administered oxaliplatin at less than one-tenth the recommended human dose based on body surface area during gestation days (GD) 1 to 5 (preimplantation), GD 6 to 10, or GD 11 to 16 (during organogenesis).
Oxaliplatin caused developmental mortality (increased early resorptions) when administered on days GD 6 to 10 and GD 11 to 16 and adversely affected fetal growth (decreased fetal weight, delayed ossification) when administered on days GD 6 to 10.
Breastfeeding considerations
Lactation (US label) US FDA label
8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating oxaliplatin [see Use in Specific Populations (8.1)]. Contraception Oxaliplatin can cause embryo-fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].
Females Advise female patients of reproductive potential to use effective contraception while receiving oxaliplatin and for 9 months after the final dose. Males Based on its mechanism action as a genotoxic drug, advise males with female partners of reproductive potential to use effective contraception while receiving oxaliplatin and for 6 months after the final dose [see Nonclinical Toxicology (13.1)].
Infertility Based on animal studies, oxaliplatin may impair fertility in males and females [see Nonclinical Toxicology (13.1)].
Mechanism of action
12.1 Mechanism of Action Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed.
Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific. In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma.
In combination with fluorouracil, oxaliplatin exhibits in vitro and in vivo antiproliferative activity greater than either compound alone in several tumor models (HT29 [colon], GR [mammary], and L1210 [leukemia]).
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics A pharmacodynamic relationship between platinum ultrafiltrate levels and clinical safety and effectiveness has not been established.
Pharmacokinetics
The remaining 85% is rapidly distributed into tissues or eliminated in the urine.
Excretion The major route of platinum elimination is renal excretion.
At five days after a single 2-hour infusion of oxaliplatin, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%.
The renal clearance of ultrafiltrable platinum is significantly correlated with GFR.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics The reactive oxaliplatin derivatives are present as a fraction of the unbound platinum in plasma ultrafiltrate. After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2, pharmacokinetic parameters expressed as ultrafiltrable platinum were Cmax of 0.814 mcg/mL and volume of distribution of 440 L.
Interpatient and intrapatient variability in ultrafiltrable platinum exposure (AUC0-48hr) assessed over 3 cycles was 23% and 6%, respectively. Distribution At the end of a 2-hour infusion of oxaliplatin, approximately 15% of the administered platinum is present in the systemic circulation. The remaining 85% is rapidly distributed into tissues or eliminated in the urine.
The decline of ultrafiltrable platinum levels following oxaliplatin administration is triphasic, including two distribution phases (t 1/2α; 0.43 hours and t 1/2β; 16.8 hours). In patients, plasma protein binding of platinum is irreversible and is greater than 90%. The main binding proteins are albumin and gamma-globulins.
Platinum also binds irreversibly and accumulates (approximately 2-fold) in erythrocytes, where it appears to have no relevant activity. No platinum accumulation was observed in plasma ultrafiltrate following 85 mg/m 2 every two weeks. Elimination The decline of ultrafiltrable platinum concentrations from plasma is characterized by a long terminal elimination phase (t 1/2 γ; 391 hour).
Metabolism Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation. There is no evidence of cytochrome P450-mediated metabolism in vitro. Up to 17 platinum-containing derivatives have been observed in plasma ultrafiltrate samples from patients, including several cytotoxic species (monochloro DACH platinum, dichloro DACH platinum, and monoaquo and diaquo DACH platinum) and a number of noncytotoxic, conjugated species.
Excretion The major route of platinum elimination is renal excretion. At five days after a single 2-hour infusion of oxaliplatin, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%. Platinum was cleared from plasma at a rate (10 to 17 L/h) that was similar to or exceeded the average human glomerular filtration rate (GFR; 7.5 L/h).
The renal clearance of ultrafiltrable platinum is significantly correlated with GFR. Special Populations Sex There was no significant effect of sex on the clearance of ultrafiltrable platinum. Patients with renal impairment Patients with normal function (CLcr greater than 80 mL/min) and patients with mild (CLcr=50 to 80 mL/min) and moderate (CLcr equal to 30 to 49 mL/min) renal impairment received oxaliplatin 85 mg/m2 and those with severe (CLcr less than 30 mL/min) renal impairment received oxaliplatin 65 mg/m 2.
Mean dose adjusted AUC of unbound platinum was 40%, 95%, and 342% higher for patients with mild, moderate, and severe renal impairment, respectively, compared to patients with normal renal function. Mean dose adjusted Cmax of unbound platinum appeared to be similar among the normal, mild and moderate renal function groups, but was 38% higher in the severe group than in the normal group [see Dosage and Administration (2.3)].
Drug Interaction Studies No pharmacokinetic interaction between oxaliplatin 85 mg/m2 and infusional fluorouracil has been observed in patients treated every 2 weeks, but increases of fluorouracil plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 of oxaliplatin administered every 3 weeks. In vitro platinum was not displaced from plasma proteins by the following medications: erythromycin, salicylate, sodium valproate, granisetron, and paclitaxel.
In vitro oxaliplatin does not inhibit human cytochrome P450 isoenzymes.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Oxaliplatin 5 mg/mL concentrate solution, 10 mL Vial | ₱1,164.35–₱1,689.00Reference ₱1,475.45 | per vial | DPRI procurement range |
| Oxaliplatin 5 mg/mL concentrate solution, 20 mL Vial | ₱1,787.00–₱2,798.00Reference ₱2,725.00 | per vial | DPRI procurement range |
| Oxaliplatin 50 mg powder Vial | ₱1,095.00–₱2,998.00Reference ₱1,165.79 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Oxaliplatin |
| PNF listing | Inj.: 5 mg/mL concentrate solution, 10 mL and 20 mL vial (IV infusion) powder, 50 mg vial (IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Oxaliplatin · Gland Pharma Limited [US FDA-approved label, version 11, August 24, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6f89dc3-a594-4b5b-8728-272e20c1ecb5
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .